PPARG and metabolic dysfunction-associated steatotic liver disease: Different studies found improved metabolic parameters and antisteatogenic effects in NAFLD upon rosiglitazone treatment, serving as a potent inducer of PPARg.[47], [48], [49], [50] Although chronic ethanol consumption was associated with an activation of PPARg2,51 PPARg2-/- mice had decreased ethanol-induced liver injury.52